CClinicalTrials.gg
CompletedNCT05847621LINCS UP: RCTUpdated Dec 17, 2025

Linking Individuals Needing Care for Substance Use Disorders to Peer Coaches

An interventional study of Peer recovery coaching with linkage to recovery resources and Usual Care in Substance Use Disorders, sponsored by Emory University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-17.

Sponsored by Emory University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a 3-arm randomized controlled trial. Participants will be randomized via a maximally tolerated imbalance randomization procedure using NCI's Clinical Trial Randomization Tool with 1:1:1 allocation to each group: in-person peer recovery coaching (PRC) with linkage to recovery resources, telemedicine-based peer recovery coaching with linkage to recovery resources, or usual care.

In the PRC arms, PRCs will meet patients at bedside (in person) or via a tablet-based video call (telemedicine). They will assess the participant's state of change, engage in motivational interviewing techniques, and link the participant to community-based recovery resources according to the needs of the participant. They will also schedule and perform follow up calls after the participant is discharged from the ED to provide ongoing support and facilitate re-linkage to recovery resources, if needed.

Participants in the usual care arm will be provided with a list of community recovery resources, but there will be no PRC interaction or direct linkage to resources through the study.

Follow up visits will take place at 7, 30, and 90 days after enrollment. Most will take place via telephone, but participants will be given the option of an in-person visit if they so desire.

Read the detailed description

Deaths from drug overdose have risen to record levels since the onset of the COVID-19 pandemic, disproportionately impacting Black individuals and people experiencing homelessness. Fewer than one-third of the 8.3 million individuals living with an illicit drug use disorder in 2019 reported receiving treatment. Telemedicine services have increased access to care for many patients living with substance use disorders (SUD), but the long-term role of this treatment approach in SUD care is uncertain. Multifaceted strategies are needed to build recovery capital and link vulnerable individuals to recovery resources.

Emergency department (ED) visits are an opportunity to screen for SUDs, initiate treatment, and link to recovery resources. Observational studies have noted that consultation with a peer recovery coach (PRC) was well-received in EDs, with high rates of engagement and satisfaction. PRCs facilitate conversations allowing patients to express their ideal pathway to recovery, provide linkage to services across the social ecology, and follow up to support recovery, including re-linkage to resources as needed. Nonetheless, their role in ED screening and linkage to resources, including the potential role of telemedicine, has not been rigorously evaluated.

The investigators will conduct a randomized controlled trial enrolling 600 subjects across three arms: in-person peer coaching with linkage to recovery support services and callbacks, telemedicine-based peer coaching with linkage and callbacks, or usual care. Results will inform other EDs considering a peer recovery coach program for patients presenting with SUD-related conditions. By utilizing telemedicine, this model will be rapidly scalable and readily implemented at other facilities.

02

Conditions studied

  • Substance Use Disorders
03

In context

Substance-Related Disorders

2,124 studies on the registry are indexed under Substance-Related Disorders; 393 are open to participants now.

This study's enrollment of 144 is above the median of 108 across 1,727 interventional studies indexed under Substance-Related Disorders.

Browse Substance-Related Disorders studies →

Lead sponsor

Emory University is the lead sponsor of 1,386 studies on the registry; 236 are open to participants now.

Of its 229 completed or terminated interventional studies of FDA-regulated products, 174 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. ED patient or hospitalized through the ED within last 24 hours
  2. Age 18 years or older
  3. Able to speak and understand English
  4. Clinically sober, able to provide informed consent
  5. Score of 3 or greater - "moderate level", "substantial level", or "severe level" of problems related to drug abuse - on Drug Abuse Screening Test (DAST-10).(103, 104)
  6. Willing to follow study procedures and complete research follow-up calls
  7. Have at least one reliable contact number

Exclusion criteria

Exclusion Criteria:

  1. Medically or psychiatrically unstable as determined by treating physician
  2. Prisoner or in police custody
  3. Prior participation in the study
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    In-person peer recovery coaching with linkage to recovery resources

    PRCs will meet patients at bedside (in person). They will also schedule and perform follow up calls after the participant is discharged from the ED to provide ongoing support and facilitate re-linkage to recovery resources, if needed. Follow-up data collection on day 7, 30, 90 post discharge.

    Behavioral: Peer recovery coaching with linkage to recovery resources

  • Experimental
    Telemedicine-based peer recovery coaching with linkage to recovery resources

    PRCs will meet patients via a tablet-based video call (telemedicine). They will also schedule and perform follow up calls after the participant is discharged from the ED to provide ongoing support and facilitate re-linkage to recovery resources, if needed. Follow-up data collection on day 7, 30, 90 post discharge.

    Behavioral: Peer recovery coaching with linkage to recovery resources

  • Active comparator
    Usual Care

    Participants in the usual care arm will be provided with a list of community recovery resources. No callbacks or re-linkage to recovery resources. Follow-up data collection on day 7, 30, 90 post discharge.

    Behavioral: Usual Care

Interventions

  • BehavioralPeer recovery coaching with linkage to recovery resources

    Peer recovery coach (PRC) assessment of the participant's state of change, engage in motivational interviewing techniques, and link the participant to community-based recovery resources according to the needs of the participant. They will also schedule and perform follow up calls after the participant is discharged from the ED to provide ongoing support and facilitate re-linkage to recovery resources, if needed.

  • BehavioralUsual Care

    Participants will be provided with a list of community recovery resources.

06

What researchers measure

Primary outcomes

  1. Change in number of participants with successful linkage to at least one recovery resource

    Change in number of participants with successful linkage to at least one recovery resource (formal addiction treatment, Recovery Community Organization (RCO), or harm reduction organization) at 30 days and 90 days after enrollment.

    Time frame: Baseline, 30 and 90 days after enrollment

Secondary outcomes

  1. Change in Brief Assessment of Recovery Capital (BARC-10)

    This outcome will be evaluated obtaining a score on a scale. The range of possible responses is 10-60. Higher score correlates with better outcome.

    Time frame: Baseline, 7, 30, and 90 days after enrollment

  2. Change in number of successful engagements with PRC after ED visit

    Change in number of successful engagements with PRC (peer recovery coach) after ED visit

    Time frame: Baseline, 7, 30, and 90 days after enrollment

  3. Change in number of episodes of re-linkage to recovery resources

    Change in number of episodes of re-linkage to recovery resources

    Time frame: Baseline, 7, 30, and 90 days post intervention

  4. Self-reported substance use in last 30 days

    Self-reported substance use in last 30 days as measured by Timeline Follow-back (TLFB). It will be reported in number of episodes per day.

    Time frame: Baseline, 30 and 90 days post intervention

  5. Number of fatal overdose events

    Number of fatal overdose events will be collected

    Time frame: 90 days post intervention

  6. Number of nonfatal overdose events

    Number of nonfatal overdose events will be collected

    Time frame: 90 days post intervention

  7. Number of Emergency Department (ED) visits

    Number of ED visits will be collected

    Time frame: 90 days post intervention

  8. Number of hospitalizations

    Number of hospitalizations will be collected

    Time frame: 90 days post intervention

  9. Change in employment status

    Choices include: disabled, employed 32 hours or more per week, employed less than 32 hours per week, full-time student, homemaker, on medical leave, only temporarily laid off/sick leave/maternity leave, other, part-time student, retired, unemployed, and unknown. This outcome would measure a change in employment status from any of the choices to another one.

    Time frame: 90 days post intervention

  10. Change in number of participants based on Housing status

    Housing status will be reported specifying one of the categories: apartment, Single family house, homeless, shelter, dormitory, multifamily house. Number of participants will be reported in each category at 0, 7, 30, 90 days post intervention.

    Time frame: Baseline, 7, 30, and 90 days post intervention

  11. Change in Social connections and isolation score

    Social isolation scores range from 0 to 4, with 0 representing the highest level of social isolation and 4 representing the lowest level.

    Time frame: Baseline, 7, 30, 90 days post intervention

07

Study locations

1 site
  • Grady Memorial Hospital
    Atlanta, Georgia 30303, United States
08

References and documents

Study documents

  • Informed consent form · Apr 11, 2025

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: Yes — Data sharing will be initiated upon written request to the PI and would ultimately be shared via a secure portal such as Microsoft OneDrive. Deidentified data files, the data dictionary, and the final protocol will be uploaded to the Emory Dataverse, which is a long-term repository offered through a partnership between Emory and the Odum Institute at the University of North Carolina and Chapel Hill. This repository has policies and procedures in place that will provide data access to qualified researchers, fully consistent with federal data sharing policies and applicable laws and regulations. Datasets are uniquely named with a persistent digital object identifier (DOI), and are downloadable directly through a web-based interface. Additional data documentation and de-identified data will be deposited for sharing along with data consistent with applicable laws and regulations. Submitted data will confirm with relevant data and terminology standards.

Supporting information: Study protocol

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05847621
Lead sponsor
Emory University
Collaborators
Centers for Disease Control and Prevention
Responsible party
Joseph Carpenter (Assistant Professor, Emory University) — Principal investigator
First posted
May 6, 2023
Start date
Aug 16, 2024
Primary completion
Sep 30, 2025
Completion
Sep 30, 2025
Last update
Dec 17, 2025

Study contacts

Joseph E Carpenter, MD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion